QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Résumé Extracto Full Text PDF Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Articles Ahead of Print [Order Reprint] Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sokolski, K. N Articles by Brown, B. J Search for Related Content PubMed PubMed Citation Articles by Sokolski, K. N Articles by Brown, B. J

Quetiapine for Insomnia Associated with Refractory Depression Exacerbated by Phenelzine

Chief, Mood Disorders Clinic, Veterans Affairs Long Beach Healthcare System, Long Beach, CA

Brenda J Brown, MA

Senior research Associate, Department of Psychiatry and Human Behavior, University of California, Irvine, CA

Reprints: Dr. Sokolski, Mood Disorders Clinic, VA Long Beach Healthcare System, 5901 E. Seventh St. (06/116a), Long Beach, CA 90822-5201, fax 562/826-5088, kenneth.sokolski{at}med.va.gov

OBJECTIVE: To report the successful treatment of phenelzine-associated insomnia with low-dose quetiapine in a patient with refractory depression.

CASE SUMMARY: A 42-year-old white man with severe major depression unresponsive to selective serotonin-reuptake inhibitors, bupropion, and tricyclic antidepressants improved following treatment with the monoamine oxidase inhibitor (MAOI) phenelzine. Insomnia, present to a moderate degree prior to antidepressant therapy, worsened markedly following phenelzine treatment and failed to respond to diphenhydramine, temazepam, triazolam, clonazepam, zolpidem, or trazodone given at high therapeutic doses. Sleep disturbance resolved with low-dose (50 mg) adjunctive quetiapine, with no adverse effects.

DISCUSSION: Major depression refractory to standard therapy is a common and serious condition. Some cases respond to MAOIs; however, orthostatic hypotension and insomnia frequently occur. Potentially serious MAOI interactions with psychotropic drugs have raised concerns about combining these agents. In this case, a failure of a number of other medications known to treat MAOI-associated insomnia safely prompted a trial of quetiapine. Despite the possibility that enhanced serotonergic activity might have resulted in serotonin syndrome, no adverse interactions between phenelzine and quetiapine were noted. The use of low-dose, once-daily quetiapine, along with its unique binding properties, may account for its increased safety in combination with phenelzine.

CONCLUSIONS: This case illustrates that low-dose quetiapine may be an alternative treatment for phenelzine-associated insomnia. Further case reports are needed to establish the safety and effectiveness of combining these agents.

Key Words: depression, insomnia, phenelzine, quetiapine

Published Online, February 14, 2006. www.theannals.com, DOI 10.1345/aph.1G416

This article has been cited by other articles:

				J. N Wine, C. Sanda, and J. Caballero Effects of Quetiapine on Sleep in Nonpsychiatric and Psychiatric Conditions Ann. Pharmacother., April 1, 2009; 43(4): 707 - 713. [Abstract] [Full Text] [PDF]

				M. J. Hanley and G. A. Kenna Quetiapine: Treatment for substance abuse and drug of abuse Am. J. Health Syst. Pharm., April 1, 2008; 65(7): 611 - 618. [Abstract] [Full Text] [PDF]